Appeal No. 1997-0483
Application No. 07/648,900
Claims 5, 6, 13, 19 and 20 are illustrative and read as follows.
5. A polypeptide consisting essentially of an amino acid sequence
which corresponds to residues 407 to 486 of a mammalian thrombomodulin
as shown in Figure 6.3
6. The polypeptide of claim 5 having the formula:
Phe Cys Asn Gln Thr Ala Cys Pro Ala Asp Cys Asp Pro Asn Thr Gln
Ala Ser Cys Glu Cys Pro Glu Gly Tyr Ile Leu Asp Asp Gly Phe Ile
Cys Thr Asp Ile Asp Glu Cys Glu Asn Gly Gly Phe Cys Ser Gly Val
Cys His Asn Leu Pro Gly Thr Phe Glu Cys Ile Cys Gly Pro Asp Ser
Ala Leu Ala Arg His Ile Gly Thr Asp Cys Asp Ser Gly Lys Val Asp.
13. A pharmaceutical composition comprising an amount of the
polypeptide of claim 5 effective to inhibit coagulation in a mammalian
subject in need thereof and a pharmaceutically acceptable carrier.
19. A method for inhibiting coagulation in a mammalian subject in
need thereof comprising administering to the subject an effective amount of
an isolated polypeptide consisting essentially of an amino acid sequence
which corresponds to residues 407 to 486 of a mammalian thrombomodulin
as shown in Figure 6 in combination with a pharmaceutically acceptable
carrier, to inhibit the clotting activity of thrombin without increasing protein C
activation.
20. The polypeptide of claim 5 which is a portion of a
thrombomodulin of an animal selected from the group consisting of human,
rabbit, and bovine.
A reference relied on by the examiner is (answer, p. 7):
3According to the specification (p. 3), "Figure 6 shows schematically the amino acid structure of
human el-TM [i.e., active elastase proteolytic product of thrombomodulin (see specification, p. 10, Example
2)] which corresponds to residues 234 to 486 of thrombomodulin. The CNBr fragments, CB1, CB2 and
CB3, begin at residues 234, 310 and 407, respectively."
- 2 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007